| SBUX |
Report |
Global comparable sales growth |
BEAT |
pred ~6.8% vs. cons 5.75% |
MEDIUM |
| SBUX |
Report |
Adjusted operating margin |
IN-LINE |
pred ~12.5% vs. cons 12.33% |
MEDIUM |
| SBUX |
Report |
Adjusted EPS |
BEAT |
pred ~$0.67 vs. cons $0.65 |
MEDIUM |
| SBUX |
Guide |
Global and U.S. comparable-sales outlook |
UNCHANGED |
guide ~5.0%+ vs. cons 5.0%+ (FY2026) |
HIGH |
| SBUX |
Guide |
Adjusted EPS outlook |
UNCHANGED |
guide ~$2.25-$2.45 vs. cons $2.38 midpoint (FY2026) |
MEDIUM |
| SBUX |
Guide |
Consolidated operating-margin outlook |
UNCHANGED |
guide ~+0.5% YoY vs. cons +0.5% YoY (FY2026) |
MEDIUM |
| SBUX |
Guide |
Consolidated revenue outlook |
UNCHANGED |
guide ~0.0% YoY vs. cons 0.0% YoY (FY2026) |
HIGH |
| SBUX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| SBUX |
Return |
5-day cumulative residual |
+0.5% (FADE) |
A ~6.8% comp and ~$0.67 EPS result should produce an initial ~2.5% residual upside versus the S&P 500, but unchanged FY2026 EPS guidance at a ~$2.35 midpoint leaves implied Q4 EPS near ~$0.77 versus an estimated ~$0.80 Street view; out-period revisions should therefore pull the five-day residual toward ~0.5%. |
MEDIUM |